Back to Search
Start Over
Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.
- Source :
-
JAMA: Journal of the American Medical Association . 11/19/2014, Vol. 312 Issue 19, p2030-2031. 2p. - Publication Year :
- 2014
-
Abstract
- <bold>Clinical Question: </bold>Is fixed-dose combination therapy (polypill) that combines antiplatelet, blood pressure-lowering, and cholesterol-lowering medications into a single pill associated with improved cardiovascular disease (CVD) risk factors or reduced all-cause mortality or fatal and nonfatal CVD events? Is the polypill associated with an increase in adverse events?<bold>Bottom Line: </bold>Polypills are associated with greater reductions in systolic blood pressure and total cholesterol compared with usual care, placebo, or active comparators, but also with a 19% higher risk of any adverse event. Due to limited power from available evidence, the association of polypills with all-cause mortality or fatal and nonfatal CVD events is uncertain. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00987484
- Volume :
- 312
- Issue :
- 19
- Database :
- Academic Search Index
- Journal :
- JAMA: Journal of the American Medical Association
- Publication Type :
- Academic Journal
- Accession number :
- 99502404
- Full Text :
- https://doi.org/10.1001/jama.2014.13616